September 20, 2026 03:14 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Arvind Kejriwal, family ‘missing’ from Delhi voter list, claims Aam Aadmi Party | ‘No UPI above ₹2,000?’ Ghaziabad traders put up ‘cash only’ hoardings | Trump signs Russia sanctions bill: India faces fresh 100% tariff threat over Moscow oil | Caught using ChatGPT for exam answers, IIT Bombay student dies by suicide; students protest | Congress' Nandigram candidate arrested after Mamata's support amid TMC symbol row; Bengal bypoll gets chaotic | Gurugram murder shocker: Groom-to-be leaves sisters at Delhi restaurant to meet ex-colleague, found dead days later | Delhi horror: Teen allegedly gangraped, stabbed to death and dumped in field; dogs eat parts of body | TMC name, symbol frozen: EC tells rival factions to pick new identities ahead of Bengal bypolls | Married just 17 days ago: Hyderabad engineer mysteriously found dead at US home | ‘We will promote cash’: New UPI charge triggers trader backlash, Opposition protests
Pregnancy
Pixabay

U.S. FDA approves first nonprescription daily oral contraceptive

| @indiablooms | Jul 14, 2023, at 03:30 pm

Los Angeles: The U.S. Food and Drug Administration (FDA) on Thursday approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy, which is the first daily oral contraceptive approved for use in the United States without a prescription.

Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.

Nonprescription availability of Opill may reduce barriers to access by allowing individuals to obtain an oral contraceptive without the need to first see a health care provider, said the FDA in a statement.

The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA.

"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.